High-Flow Nasal Cannula (HFNC) 

1. Introduction

High-Flow Nasal Cannula (HFNC) is an advanced oxygen delivery system that delivers heated, humidified oxygen–air mixture at high flow rates (up to 60–70 L/min) with a precise and adjustable FiO₂ (21–100%).

➡️ In conventional nasal prongs → YES, flow determines FiO₂.

➡️ In HFNC → NO, FiO₂ is independent of flow (when flow ≥ patient inspiratory demand).


2. Components of HFNC System

HFNC consists of:

  1. Air–oxygen blender → Delivers precise FiO₂ (21–100%)
  2. Flow generator → Provides high flow up to 60–70 L/min
  3. Heated humidifier → Maintains gas at 31–37°C
  4. Heated circuit tubing → Prevents condensation
  5. Wide-bore nasal cannula → Comfortable high-flow interface

Why heating and humidification are crucial?

  • Prevents mucosal injury
  • Maintains mucociliary function
  • Improves secretion clearance
  • Enhances tolerance

Exam point: Dry high-flow oxygen causes epithelial damage and ciliary dysfunction.


3. Physiological Effects of HFNC

HFNC is not “just high oxygen.” It has multiple physiological mechanisms:


3.1 High FiO₂ Delivery

Unlike conventional nasal prongs:

  • Delivers stable and predictable FiO₂
  • Minimizes room air entrainment

Useful in:

  • Severe hypoxemia
  • ARDS
  • Pneumonia


3.2 Dead Space Washout

HFNC flushes nasopharyngeal dead space:

  • Reduces CO₂ rebreathing
  • Improves ventilatory efficiency
  • Reduces work of breathing

Important in:

  • Mild hypercapnia
  • Post-extubation support


3.3 Generation of Positive Airway Pressure

HFNC generates low-level PEEP (3–5 cm H₂O):

  • Increases end-expiratory lung volume
  • Prevents alveolar collapse
  • Improves oxygenation

PEEP effect increases with:

  • Higher flow
  • Closed mouth breathing

Exam point: HFNC ≠ NIV, but provides mild CPAP-like effect.


3.4 Reduced Work of Breathing

Mechanisms:

  • Reduced inspiratory resistance
  • Better lung compliance
  • Improved oxygenation

Clinical markers:

  • ↓ Respiratory rate
  • ↓ Accessory muscle use
  • ↓ Dyspnea score


3.5 Improved Secretion Clearance

Humidification:

  • Maintains mucus viscosity
  • Enhances ciliary activity
  • Prevents crust formation

Very useful in:

  • Post-extubation
  • Bronchiectasis
  • Pneumonia


4. Indications of HFNC

4.1 Acute Hypoxemic Respiratory Failure (AHRF)

Strongest Evidence Area

Landmark trial:

  • FLORALI trial

Key findings:

  • Lower intubation rates (especially PaO₂/FiO₂ < 200)
  • Lower 90-day mortality vs NIV

Preferred in:

  • ARDS (mild–moderate)
  • Severe pneumonia
  • Viral pneumonitis (including COVID era practice)


4.2 Post-Extubation Support

  • Reduces reintubation in low–moderate risk patients
  • Alternative to NIV in selected cases

High-risk extubation:

  • HFNC + NIV may be superior


4.3 Preoxygenation Before Intubation

Advantages:

  • Provides apneic oxygenation
  • Delays desaturation
  • Improves safe apnea time

Especially useful in:

  • Obese patients
  • Hypoxemic patients
  • ARDS


4.4 Postoperative Hypoxemia

Useful after:

  • Major abdominal surgery
  • Thoracic surgery
  • Cardiac surgery

Improves comfort compared to NIV.


4.5 Palliative / DNI Patients

HFNC:

  • More comfortable than NIV
  • Allows talking and eating
  • Reduces dyspnea


5. Contraindications

Absolute:

  • Immediate need for intubation
  • Respiratory arrest
  • Severe hemodynamic instability
  • Altered sensorium with aspiration risk

Relative:

  • Severe hypercapnic respiratory failure (unless mild and monitored)
  • Facial trauma

 HFNC is NOT first-line for severe COPD exacerbation with acidosis → NIV preferred.


6. HFNC vs NIV – Comparison

Feature

HFNC

NIV

Interface

Nasal cannula

Tight mask

PEEP

Low (3–5 cm H₂O)

Adjustable high PEEP

CO₂ removal

Mild

Significant

Tolerance

Excellent

Moderate

Hypercapnia

Limited role

Strong evidence

ARDS

Good in mild–moderate

Mixed results


7. Starting Settings in ICU

Initial Settings:

  • Flow: 40–60 L/min
  • FiO₂: 1.0 initially in severe hypoxemia
  • Temperature: 34–37°C

Then titrate:

  • Target SpO₂: 92–96% (88–92% in COPD)

Higher flow = better PEEP + better washout.


8. Monitoring HFNC Therapy

Monitor:

  • Respiratory rate
  • Work of breathing
  • SpO₂
  • ABG
  • Hemodynamics


8.1 ROX Index 

ROX = (SpO₂ / FiO₂) ÷ Respiratory Rate

Interpretation:

  • 4.88 at 12 hours → Success likely
  • <3.85 → High failure risk

Derived from:

  • ROX index study


Weaning from High-Flow Nasal Cannula

1. When to Consider Weaning?

Clinical Stability Criteria

Patient should have:

  • RR < 22–24/min
  • Minimal accessory muscle use
  • Hemodynamic stability
  • Improving primary pathology
  • Stable mental status
  • SpO₂ target achieved

Oxygenation Criteria

  • FiO₂ ≤ 0.4–0.5
  • SpO₂ ≥ 92–96% (88–92% in COPD)
  • ROX index > 4.88

(ROX = [SpO₂/FiO₂] ÷ RR)


2. Core Principle: What to Reduce First?

 Always reduce FiO₂ first, then flow.

Why?

  • FiO₂ reduction confirms oxygenation recovery.
  • Flow provides:
    • Dead space washout
    • Low-level PEEP
    • Work-of-breathing reduction

If you reduce flow first → risk alveolar derecruitment.


3. Stepwise Weaning Protocol

Step 1 – Reduce FiO₂

If FiO₂ > 0.4:

  • Reduce by 5–10% every 30–60 min
  • Maintain target SpO₂

Target before moving to flow reduction:

  • FiO₂ ≤ 0.4


Step 2 – Reduce Flow

Once FiO₂ ≤ 0.4:

  • Reduce flow in steps of 5–10 L/min
  • Reassess after each reduction (30–60 min)

Typical sequence:

  • 60 → 50 → 40 → 35 → 30 L/min

Most patients tolerate 25–30 L/min before switching.


Step 3 – Transition to Conventional Oxygen

When:

  • Flow ≤ 25–30 L/min
  • FiO₂ ≤ 0.4
  • RR stable
  • Minimal distress

Switch to:

  • Nasal prongs 2–5 L/min
  • Venturi mask if controlled FiO₂ needed

Monitor closely for 1–2 hours after switch.


Scroll to Top